Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia
Nobuko Hijiya(Lurie Children's Hospital), Paul S. Gaynon(University of Southern California), Peter G. Steinherz(Memorial Sloan Kettering Cancer Center), Richard Kadota(Roswell Park Comprehensive Cancer Center), Todd M. Cooper(Seattle Children's Hospital), Elly Barry, Sima Jeha(St. Jude Children's Research Hospital), Jaideep V. Thottassery(Southern Research Institute), Lewis B. Silverman(Columbia University Irving Medical Center), Kelly W. Maloney(Children's Hospital Colorado), William L. Carroll(NYU Langone Health), Blythe Thomson(Epizyme (United States)), Michael J. Borowitz(Johns Hopkins University), Gary V. Dahl(Lucile Packard Children's Hospital), J Paul, Violet Shen(Ruhr University Bochum), Michael S. Isakoff(Center for Cancer and Blood Disorders)
Cited by 122
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2012|1.2k